New pyrazolylindolin-2-one linked coumarin derivatives were designed as dual BRAFV600E/VEGFR-2 inhibitors targeting melanoma cells A375. Docking simulation showed various interactions with the binding residues in BRAFV600E and VEGFR-2 active sites.
24 February 2020 in Journal of Heterocyclic Chemistry